Synapse - Gilles Salles

Results (304)

The POLARIX study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma

Meeting Abstract

Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; more...
Blood (2021)

Fulltext@MSK | Save

Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20-containing chemoimmunotherapy (POD24)

Meeting Abstract

Jacobson, C. A.; Chavez, J. C.; Sehgal, A.; William, B. M.; Munoz, J.; Salles, G. A.; Casulo, C.; Munshi, P. N.; Maloney, D. G.; De Vos, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5

Meeting Abstract

Chavez, J. C.; Jacobson, C. A.; Sehgal, A.; Neelapu, S. S.; Maloney, D. G.; Salles, G. A.; William, B. M.; Yang, Y.; Goyal, L.; Chou, J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in US routine clinical practice

Meeting Abstract

Martin, P.; Wang, M.; Kumar, A.; Qi, K.; Daly, K.; Parisi, L.; Zhu, A.; Salles, G. A.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Journal Article

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Idelalisib immune-related toxicity is associated with improved treatment response

Journal Article

Wagner-Johnston, N. D.; Sharman, J.; Furman, R. R.; Salles, G.; Brown, J. R.; Robak, T.; Gu, L.; Xing, G.; Chan, R. J.; Rajakumaraswamy, N.; more...
Leukemia and Lymphoma (2021)

Fulltext@MSK | Save

Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: Is 4 Gy suitable for curable patients?

Journal Article

Imber, B. S.; Chau, K. W.; Lee, J.; Lee, J.; Casey, D. L.; Yang, J. C.; Wijentunga, N. A.; Shepherd, A.; Hajj, C.; Qi, S.; more...
Blood Advances (2021)

Fulltext@MSK | Save

Overall survival with tafasitamab + lenalidomide (LEN) vs routinely administered therapies for ASCT-ineligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Outcomes from the observational RE-MIND2 study

Meeting Abstract

Nowakowski, G. S.; Yoon, D. H.; Mondello, P.; Joffe, E.; Peters, A.; Fleury, I.; Greil, R.; Ku, M.; Marks, R.; Kim, K.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials